Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Pembrolizumab for Treatment of PMBCL

Jun 19, 2018, 10:20 AM
URL:
On June 13, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy.

Read the FDA press release here.

Posted 6/19/2018

Leave a comment